Abstract
RATIONALE AND OBJECTIVE: SJP-005 (ketotifen and ibuprofen) is being developed as a potential new treatment for opioid withdrawal. Three studies were conducted to evaluate the early phase (acute, day 1) and late phase (days 2-12) effects of SJP-005 on discontinuation-induced morphine withdrawal. METHODS: Sprague-Dawley rats received subcutaneous morphine twice daily
... read more